NYSE : EVMN
Evommune, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 6.73 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 244.25M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.
Details
| Name | Evommune, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 48 |
| Founded | 2020 |
| Ipo Date | 2025-11-06 |
| Ceo | Luis Pena |
| Country | United States |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 16.00 |
| Isin | US30054Y1073 |
| Cusip | 30054Y107 |
| Cik | 2044725 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Luis C. Pena | Founder, President, Chief Executive Officer and Director |
| Kyle Carver CPA, M.B.A. | Chief Financial Officer |
| Gregory S. Moss Esq. | Chief Business and Legal Officer, Corporate Secretary and Chief Compliance Officer |
| Dr. Eugene Andrew Bauer M.D. | Co-Founder, Chief Medical Officer and Director |
| Dr. Jeegar Patel Ph.D. | Chief Scientific Officer |
| Janice Drew M.P.H. | Chief of Development Operations |
| Dr. Lou Sehl Ph.D. | Senior Vice President of Technical Operations |
| Dr. Daniel J. Burge M.d. | Senior Vice President of Clinical Development |
| J. Mark Jackson M.D. | Senior Vice President of Clinical Development |
Contact
| Address | 1891 Page Mill Road, Palo Alto, California 94304, United States |
| Phone | (925) 247-4481 |
| Website | https://www.evommune.com |